Lijst met verwijzingen naar andere richtlijnen
Uit Richtlijnen HIV
(Verschil tussen bewerkingen)
Regel 4: | Regel 4: | ||
|- | |- | ||
| valign="top" align="left" | '''Pagina'''<br> | | valign="top" align="left" | '''Pagina'''<br> | ||
- | | width="45" valign="top" align="left" | '''Link naar andere richtlijn'''[[ | + | | width="45" valign="top" align="left" | '''Link naar andere richtlijn'''[[|<br>]] |
|- | |- | ||
- | | valign="top" align="left" | [[ | + | | valign="top" align="left" | [[Inhoud]] |
| width="45" valign="top" align="left" | SOA richtlijn<br>PrEP richtlijn | | width="45" valign="top" align="left" | SOA richtlijn<br>PrEP richtlijn | ||
|- | |- | ||
Regel 15: | Regel 15: | ||
| width="45" valign="top" align="left" | Aidsinfo NIH | | width="45" valign="top" align="left" | Aidsinfo NIH | ||
|- | |- | ||
- | | valign="top" align="left" | | + | | valign="top" align="left" | [[2.2._Keuze_van_antiretrovirale_therapie_bij_naïeve_volwassenen_met_hiv|2.2. Keuze van antiretrovirale therapie bij naïeve volwassenen met hiv]]<br> |
- | + | ||
- | + | ||
- | + | ||
- | | | + | |
- | + | ||
- | + | ||
| width="45" valign="top" align="left" | Aidsinfo NIH | | width="45" valign="top" align="left" | Aidsinfo NIH | ||
|- | |- | ||
- | | valign="top" align="left" | [[ | + | | valign="top" align="left" | [[2.3._Tijdelijk_onderbreken_van_antiretrovirale_therapie|2.3. Tijdelijk onderbreken van antiretrovirale therapie]]<br> |
- | + | ||
- | + | ||
- | + | ||
| width="45" valign="top" align="left" | Aidsinfo NIH | | width="45" valign="top" align="left" | Aidsinfo NIH | ||
|- | |- | ||
- | | valign="top" align="left" | [[ | + | | valign="top" align="left" | [[2.4._Richtlijn_anti-retrovirale_therapie_bij_voorbehandelde_mensen_met_hiv|2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv]]<br> |
- | + | ||
- | + | ||
- | + | ||
| width="45" valign="top" align="left" | Aidsinfo NIH | | width="45" valign="top" align="left" | Aidsinfo NIH | ||
|- | |- | ||
Regel 39: | Regel 27: | ||
| width="45" valign="top" align="left" | <br> | | width="45" valign="top" align="left" | <br> | ||
|- | |- | ||
- | | valign="top" align="left" | '''[[Hoofdstuk 3. Behandeling van | + | | valign="top" align="left" | '''[[Hoofdstuk_3._Behandeling_van_hiv-1_infectie_bij_kinderen|Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen]]''' |
- | | width="45" valign="top" align="left" | | + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>Kinderformularium |
- | Aidsinfo NIH | + | |
- | + | ||
|- | |- | ||
| valign="top" align="left" | <br> | | valign="top" align="left" | <br> | ||
Regel 48: | Regel 34: | ||
|- | |- | ||
| valign="top" align="left" | '''[[Hoofdstuk 4. Monitoring]]<br>''' | | valign="top" align="left" | '''[[Hoofdstuk 4. Monitoring]]<br>''' | ||
- | | width="45" valign="top" align="left" | | + | | width="45" valign="top" align="left" | Aidsinfo NIH |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
|- | |- | ||
| valign="top" align="left" | [[4.2. Spiegelbepaling]]<br> | | valign="top" align="left" | [[4.2. Spiegelbepaling]]<br> | ||
- | | width="45" valign="top" align="left" | <br> | + | | width="45" valign="top" align="left" | Aidsinfo NIH<br>TDM-protocollen |
|- | |- | ||
| valign="top" align="left" | [[4.3. Resistentiebepalingen]]<br> | | valign="top" align="left" | [[4.3. Resistentiebepalingen]]<br> | ||
- | | width="45" valign="top" align="left" | <br> | + | | width="45" valign="top" align="left" | IAS-USA<br>EACS |
|- | |- | ||
| valign="top" align="left" | <br> | | valign="top" align="left" | <br> | ||
| width="45" valign="top" align="left" | <br> | | width="45" valign="top" align="left" | <br> | ||
|- | |- | ||
- | | valign="top" align="left" | '''[[Hoofdstuk 5. Diagnostiek en behandeling primaire | + | | valign="top" align="left" | '''[[Hoofdstuk_5._Diagnostiek_en_behandeling_primaire_hiv-infectie|Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie]]<br>''' |
| width="45" valign="top" align="left" | Aidsinfo NIH | | width="45" valign="top" align="left" | Aidsinfo NIH | ||
|- | |- | ||
Regel 206: | Regel 174: | ||
RIVM rapport | RIVM rapport | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
Versie op 25 okt 2018 13:30
In onderstaande tabel staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld: